Table 2. Demographic and clinical characteristics (phase 3) (n = 334).
| Group 1. Healthcare Providers (n = 124) |
Group 2. Patients under OAC treatment (n = 113) |
Group 3. General public (n = 97) |
||
|---|---|---|---|---|
| n (%) | n (%) | n (%) | ||
| Gender | ||||
| Male | 38 (30.6) | 72 (63.7) | 49 (50.5) | |
| Female | 86 (69.4) | 41 (36.3) | 48 (49.5) | |
| Marital Status | ||||
| Married | 63 (50.8) | 90 (79.6) | 59 (60.8) | |
| Unmarried | 61 (49.2) | 23 (20.4) | 38 (39.2) | |
| Nationality | ||||
| Italian | 124 (100.0) | 109 (96.5) | 97 (100.0) | |
| Foreigners | NA | 4 (3.5) | NA | |
| Education | ||||
| Primary school | NA | 44 (38.9)a | 20 (20.6) | |
| High school | 27 (21.8) | 58 (51.3)a | 61 (62.9) | |
| Bachelor Degree | 74 (59.7) | 11 (9.7)a | 16 (16.5) | |
| Post graduate | 23 (18.5) | NA | NA | |
| Employment | ||||
| Employed | 124 (100.00)* | 17 (15.0) | 66 (68.0) | |
| Not employed | NA | 16 (14.2) | 12 (12.4) | |
| Retired | NA | 80 (70.8) | 19 (19.6) | |
| Type of anticoagulation treatment | ||||
| DOAC | NA | 8 (7.1) | NA | |
| VKA | NA | 105 (92.9) | NA | |
| Clinical indication for anticoagulation treatment | ||||
| VTE | NA | 17 (15.0)a | NA | |
| AF | NA | 70 (61.9)a | NA | |
| Heart Valve Prothesis | NA | 24 (21.2)a | NA | |
| PTA | NA | 1 (0.9)a | NA | |
| Thromboembolic or Bleeding complications § | ||||
| Yes | NA | 6 (5.3) | NA | |
| Not | NA | 107 (94.6) | NA | |
| Time in treatment | ||||
| ≥ 3 months | NA | 4 (3.5) | NA | |
| ≥ 6 months | NA | 9 (7.9) | NA | |
| ≥ 12 months | NA | 22 (19.4) | NA | |
| ≥ 36 months | NA | 78 (69.0) | NA | |
| Quality of anticoagulation control | ||||
| TTR° 65–70% | NA | 45 (39.8) | NA | |
| CCI | ||||
| No comorbidities | NA | 2 (1.7) | 69 (73.4) | |
| 1–2 | 90 (79.6) | 23 (24.4) | ||
| 3–4 | 21 (18.5) | 2 (2.1) | ||
| Mean (SD) | Mean (SD) | Mean (SD) | ||
| Age (years) | 37.79 (10.63) | 71.66 (9.86) | 50.44 (17.57) | |
NA: Not applicable
* Health professionals: (a) Nurses (n = 118; 95.2%); (b) Physician (n = 5; 4.0%); Pharmacist (n = 1; 0.8%)
DOAC: Direct Acting Oral Anticoagulant
VKA: Vitamin K Antagonist
VTE: Venous Thromboembolism; this group also includes Ictus (n = 2; 1.8%) and Acute Myocardial Infarction (n = 2; 1.8%)
AF: Atrial Fibrillation (n = 36; 31.8%); Atrial Flutter (n = 2; 1.7%); Persistent atrial fibrillation (n = 32; 28.3%)
Heart Valve Prosthesis: includes, Mitral Valve Replacement (n = 8; 7.1%) and Aortic Valve Replacement (n = 16; 14.1%)
PTA: Percutaneous Transluminal Angioplasty
§ Thromboembolic or Bleeding complication in the last three months
° Time in Therapeutic Range (TTR) within 65–70% is a good standard of reference in the last three months
a Percentage may not reach the 100% of the category representation, due to the pairwise management of the missing values